NCT00157092View on ClinicalTrials.gov

Study of the Effect of Aerosolized, Recombinant Alpha 1-Antitrypsin on Epithelial Lining Fluid Analytes in Subjects With Alpha 1-Antitrypsin Deficiency

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

March 1, 2004

Primary Completion Date

October 14, 2004

Study Completion Date

October 14, 2004

Conditions
Alpha1-antitrypsin Deficiency
Interventions
DRUG

Aerosolized, Recombinant Alpha 1-Antitrypsin

Trial Locations (1)

32610

Shands Hospital at the University of Florida, Gainesville

Sponsors
All Listed Sponsors
collaborator

Arriva Pharmaceuticals, Inc.

INDUSTRY

lead

Baxalta now part of Shire

INDUSTRY

NCT00157092 - Study of the Effect of Aerosolized, Recombinant Alpha 1-Antitrypsin on Epithelial Lining Fluid Analytes in Subjects With Alpha 1-Antitrypsin Deficiency | Biotech Hunter | Biotech Hunter